ALSE Stock Overview
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Alseres Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.005 |
52 Week High | US$0.01 |
52 Week Low | US$0.005 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.92% |
5 Year Change | -99.97% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
ALSE | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -4.2% | -3.7% |
1Y | n/a | -2.0% | 20.5% |
Return vs Industry: Insufficient data to determine how ALSE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ALSE performed against the US Market.
Price Volatility
ALSE volatility | |
---|---|
ALSE Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALSE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALSE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | n/a | n/a | www.alseres.com |
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007.
Alseres Pharmaceuticals, Inc. Fundamentals Summary
ALSE fundamental statistics | |
---|---|
Market cap | US$30.00 |
Earnings (TTM) | -US$776.64k |
Revenue (TTM) | US$473.73k |
0.0x
P/S Ratio0.0x
P/E RatioIs ALSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALSE income statement (TTM) | |
---|---|
Revenue | US$473.73k |
Cost of Revenue | US$25.53k |
Gross Profit | US$448.20k |
Other Expenses | US$1.22m |
Earnings | -US$776.64k |
Last Reported Earnings
Jun 30, 2014
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ALSE perform over the long term?
See historical performance and comparison